Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics
Background Psoriasis is a chronic skin disease, and topical sequential therapy with a combination of calcipotriol and calcipotriol betamethasone is currently approved topical treatment. However, the exact mechanism by which this treatment regimen relieves psoriasis is unknown. Method We assembled a...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2023.2248318 |
| _version_ | 1797683474404999168 |
|---|---|
| author | Jingwen Cui Xiaomei Zhang Jingwen Deng Yuhong Yan Danni Yao Hao Deng Jingjie Yu Shuyan Ye Ling Han Xiaobo Yu Chuanjian Lu |
| author_facet | Jingwen Cui Xiaomei Zhang Jingwen Deng Yuhong Yan Danni Yao Hao Deng Jingjie Yu Shuyan Ye Ling Han Xiaobo Yu Chuanjian Lu |
| author_sort | Jingwen Cui |
| collection | DOAJ |
| description | Background Psoriasis is a chronic skin disease, and topical sequential therapy with a combination of calcipotriol and calcipotriol betamethasone is currently approved topical treatment. However, the exact mechanism by which this treatment regimen relieves psoriasis is unknown. Method We assembled a cohort of 65 psoriasis patients and divided post-treatment cohort into responder group and non-responder group according to the Psoriasis Area Severity Index (PASI) score after 12-week treatment. We measured the expression levels of proteins in collected 130 serum samples using our in-depth proteomics platform with a data-independent acquisition mass spectrometer and antibody microarray. We performed bioinformatics analyses of the biologic processes and signaling pathways that were changed in the responder group and constructed a proteomics landscape of psoriasis pathogenesis response to treatment. We then validated the biomarkers of disease severity in an independent cohort of 88 samples using an enzyme-linked immunosorbent assay. Results We first identified 174 differentially expressed proteins (DEPs) for comparative analysis of proteins between responders and non-responders at baseline (p < 0.05). Then pathway analysis showed that the responders focused more on signaling molecules and interaction, complement and coagulation cascades, whereas the non-responders more on signal transduction and IL-17 signaling pathways. We further identified four candidate biomarkers (COLEC11, C1QA, BNC2, ITIH4) response to treatment. We also found 125 DEPs (p < 0.05) after treatment compared with before treatment in responder group. Pathway analysis showed an enrichment in pathways related to complement and coagulation cascades, phagosome, ECM-receptor interaction, cholesterol metabolism, vitamin digestion and absorption. CD14 was validated as potential biomarkers for the disease severity of psoriasis and treatment targets. Conclusion In this work, we analyzed the response to topical sequential therapy and finally identified four biomarkers. Additionally, we found that topical sequential therapy may alleviate psoriasis by regulating lipid metabolism and modulating the immune response by affecting the complement activation process. |
| first_indexed | 2024-03-12T00:14:56Z |
| format | Article |
| id | doaj.art-70771f8e38e8487a9b112b613bb4ad3a |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:14:56Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-70771f8e38e8487a9b112b613bb4ad3a2023-09-15T14:40:43ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532023-12-0134110.1080/09546634.2023.22483182248318Potential biomarkers for psoriasis topical treatment by in-depth serum proteomicsJingwen Cui0Xiaomei Zhang1Jingwen Deng2Yuhong Yan3Danni Yao4Hao Deng5Jingjie Yu6Shuyan Ye7Ling Han8Xiaobo Yu9Chuanjian Lu10The Second Clinical College of Guangzhou University of Chinese MedicineState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences, Beijing Institute of LifeomicsState Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical SciencesState Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical SciencesState Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical SciencesState Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical SciencesState Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical SciencesState Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical SciencesThe Second Clinical College of Guangzhou University of Chinese MedicineState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences, Beijing Institute of LifeomicsThe Second Clinical College of Guangzhou University of Chinese MedicineBackground Psoriasis is a chronic skin disease, and topical sequential therapy with a combination of calcipotriol and calcipotriol betamethasone is currently approved topical treatment. However, the exact mechanism by which this treatment regimen relieves psoriasis is unknown. Method We assembled a cohort of 65 psoriasis patients and divided post-treatment cohort into responder group and non-responder group according to the Psoriasis Area Severity Index (PASI) score after 12-week treatment. We measured the expression levels of proteins in collected 130 serum samples using our in-depth proteomics platform with a data-independent acquisition mass spectrometer and antibody microarray. We performed bioinformatics analyses of the biologic processes and signaling pathways that were changed in the responder group and constructed a proteomics landscape of psoriasis pathogenesis response to treatment. We then validated the biomarkers of disease severity in an independent cohort of 88 samples using an enzyme-linked immunosorbent assay. Results We first identified 174 differentially expressed proteins (DEPs) for comparative analysis of proteins between responders and non-responders at baseline (p < 0.05). Then pathway analysis showed that the responders focused more on signaling molecules and interaction, complement and coagulation cascades, whereas the non-responders more on signal transduction and IL-17 signaling pathways. We further identified four candidate biomarkers (COLEC11, C1QA, BNC2, ITIH4) response to treatment. We also found 125 DEPs (p < 0.05) after treatment compared with before treatment in responder group. Pathway analysis showed an enrichment in pathways related to complement and coagulation cascades, phagosome, ECM-receptor interaction, cholesterol metabolism, vitamin digestion and absorption. CD14 was validated as potential biomarkers for the disease severity of psoriasis and treatment targets. Conclusion In this work, we analyzed the response to topical sequential therapy and finally identified four biomarkers. Additionally, we found that topical sequential therapy may alleviate psoriasis by regulating lipid metabolism and modulating the immune response by affecting the complement activation process.http://dx.doi.org/10.1080/09546634.2023.2248318calcipotriolcalcipotriol betamethasonepsoriasisserum proteomicsbiomarkerantibody microarray;dia-ms |
| spellingShingle | Jingwen Cui Xiaomei Zhang Jingwen Deng Yuhong Yan Danni Yao Hao Deng Jingjie Yu Shuyan Ye Ling Han Xiaobo Yu Chuanjian Lu Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics Journal of Dermatological Treatment calcipotriol calcipotriol betamethasone psoriasis serum proteomics biomarker antibody microarray;dia-ms |
| title | Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics |
| title_full | Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics |
| title_fullStr | Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics |
| title_full_unstemmed | Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics |
| title_short | Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics |
| title_sort | potential biomarkers for psoriasis topical treatment by in depth serum proteomics |
| topic | calcipotriol calcipotriol betamethasone psoriasis serum proteomics biomarker antibody microarray;dia-ms |
| url | http://dx.doi.org/10.1080/09546634.2023.2248318 |
| work_keys_str_mv | AT jingwencui potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics AT xiaomeizhang potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics AT jingwendeng potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics AT yuhongyan potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics AT danniyao potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics AT haodeng potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics AT jingjieyu potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics AT shuyanye potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics AT linghan potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics AT xiaoboyu potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics AT chuanjianlu potentialbiomarkersforpsoriasistopicaltreatmentbyindepthserumproteomics |